JP2022512689A5 - - Google Patents
Info
- Publication number
- JP2022512689A5 JP2022512689A5 JP2021520223A JP2021520223A JP2022512689A5 JP 2022512689 A5 JP2022512689 A5 JP 2022512689A5 JP 2021520223 A JP2021520223 A JP 2021520223A JP 2021520223 A JP2021520223 A JP 2021520223A JP 2022512689 A5 JP2022512689 A5 JP 2022512689A5
- Authority
- JP
- Japan
- Prior art keywords
- gene therapy
- therapy vector
- vector according
- protein
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862744069P | 2018-10-10 | 2018-10-10 | |
| US62/744,069 | 2018-10-10 | ||
| PCT/US2019/055679 WO2020077114A2 (en) | 2018-10-10 | 2019-10-10 | Disulfide bond stabilized polypeptide compositions and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512689A JP2022512689A (ja) | 2022-02-07 |
| JP2022512689A5 true JP2022512689A5 (https=) | 2022-09-21 |
| JP7577650B2 JP7577650B2 (ja) | 2024-11-05 |
Family
ID=68425288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520223A Active JP7577650B2 (ja) | 2018-10-10 | 2019-10-10 | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11097015B2 (https=) |
| EP (1) | EP3863663A2 (https=) |
| JP (1) | JP7577650B2 (https=) |
| KR (1) | KR102743734B1 (https=) |
| CN (1) | CN113631182B (https=) |
| AR (1) | AR116624A1 (https=) |
| AU (1) | AU2019359385B2 (https=) |
| BR (1) | BR112021006829A2 (https=) |
| CA (1) | CA3115944A1 (https=) |
| CL (1) | CL2021000883A1 (https=) |
| EA (1) | EA202190999A1 (https=) |
| IL (1) | IL282205A (https=) |
| MX (1) | MX2021004188A (https=) |
| PH (1) | PH12021550789A1 (https=) |
| SG (1) | SG11202103640VA (https=) |
| TW (1) | TW202027781A (https=) |
| WO (1) | WO2020077114A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102712926B1 (ko) | 2016-10-20 | 2024-10-07 | 상가모 테라퓨틱스, 인코포레이티드 | 파브리병의 치료를 위한 방법 및 조성물 |
| CN113631182B (zh) | 2018-10-10 | 2025-03-21 | 阿米库斯治疗学公司 | 二硫键稳定的多肽组合物和使用方法 |
| KR20210148101A (ko) | 2019-02-04 | 2021-12-07 | 프리라인 테라퓨틱스 리미티드 | 폴리뉴클레오티드 |
| AU2021356684A1 (en) * | 2020-10-09 | 2023-05-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| AR124981A1 (es) * | 2021-02-26 | 2023-05-24 | Takeda Pharmaceuticals Co | Composición y métodos para el tratamiento de la enfermedad de fabry |
| KR20240133693A (ko) * | 2021-11-12 | 2024-09-04 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 점액다당류증 iiia의 치료를 위한 유전자 요법 |
| WO2023086939A1 (en) * | 2021-11-12 | 2023-05-19 | Amicus Therapeutics, Inc. | Compositions and methods for treating mucopolysaccharidosis iiia |
| US20240408157A1 (en) * | 2021-12-02 | 2024-12-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| KR20250161626A (ko) * | 2023-03-20 | 2025-11-17 | 스파크 테라퓨틱스, 인코포레이티드 | Ppt1 유전자 치료 |
| WO2025092951A1 (en) * | 2023-11-03 | 2025-05-08 | Shanghai Vitalgen Biopharma Co., Ltd. | Recombinant adeno-associated viral vectors for treating fabry disease |
| WO2025264978A2 (en) | 2024-06-20 | 2025-12-26 | Amicus Therapeutics, Inc. | Recombinant alpha-galactosidase a proteins and gene therapy |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1133517T3 (da) | 1998-11-24 | 2009-11-23 | Bristol Myers Squibb Co | Intranuklear målrettet transport af forbindelser ved hjælp af 70 kd varmeshock-protein |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| EP1118334A1 (en) | 2000-01-11 | 2001-07-25 | Aventis Behring Gesellschaft mit beschränkter Haftung | Method for the production of conjugates and uses thereof for the prevention and treatment of allergic reactions and autoimmune diseases |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| WO2002087510A2 (en) | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| AU2002347910A1 (en) | 2001-10-16 | 2003-04-28 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| ES2371913T3 (es) | 2003-01-22 | 2012-01-11 | Duke University | Constructos mejorados para expresar polipéptidos lisosomales. |
| EP1620133B1 (en) | 2003-05-01 | 2015-12-09 | Genzyme Corporation | Gene therapy for neurometabolic disorders |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| EP1689766B1 (en) | 2003-11-06 | 2012-04-25 | Danisco US Inc. | Expression in filamentous fungi of protease inhibitors and variants thereof |
| CA2553955C (en) | 2004-02-10 | 2012-08-28 | Zystor Therapeutics, Inc. | Acid alpha-glucosidase and fragments thereof |
| US8889127B2 (en) | 2004-07-01 | 2014-11-18 | Icahn School Of Medicine At Mount Sinai | Targeted protein replacement for the treatment of lysosomal storage disorders |
| DE602007007923D1 (de) | 2006-04-11 | 2010-09-02 | Csl Behring Gmbh | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide |
| EP2099523A2 (en) | 2006-11-13 | 2009-09-16 | ZyStor Therapeutics , Inc. | Methods for treating pompe disease |
| JP5627571B2 (ja) | 2008-05-07 | 2014-11-19 | バイオマリン ファーマシューティカル インコーポレイテッド | リソソーム標的化ペプチドおよびその使用 |
| ES3000111T3 (en) | 2009-02-13 | 2025-02-27 | Immunomedics Inc | Intermediates for preparing conjugates with an intracellularly-cleavable linkage |
| ES2829199T3 (es) | 2010-11-22 | 2021-05-31 | Amicus Therapeutics Inc | Nuevas secuencias de señalización para mejorar la expresión y segregación de proteínas de enzimas recombinantes y otras proteínas |
| US8580922B2 (en) | 2011-03-04 | 2013-11-12 | Shire Human Genetic Therapies, Inc. | Peptide linkers for polypeptide compositions and methods for using same |
| CN103443273B (zh) | 2011-03-16 | 2016-10-26 | 天野酶制品株式会社 | 修饰型α-葡萄糖苷酶及其用途 |
| HRP20180291T1 (hr) | 2011-05-27 | 2018-03-23 | Amicus Therapeutics, Inc. | Postupci za sparivanje ciljajućeg peptida na rekombinantne lizosomalne enzime za poboljšano liječenje lizosomskih bolesti nakupljanja |
| CA3140358A1 (en) * | 2012-07-31 | 2014-02-06 | Bioasis Technologies, Inc. | Dephosphorylated lysosomal storage disease proteins and methods of use thereof |
| ES2729997T3 (es) | 2012-11-27 | 2019-11-07 | Biomarin Pharm Inc | Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas |
| AU2014228231B2 (en) | 2013-03-15 | 2019-02-21 | Amicus Therapeutics, Inc. | Chemical crosslinkers |
| CN105745326A (zh) | 2013-10-24 | 2016-07-06 | 优尼科Ip有限公司 | 用于基因治疗神经疾病的aav-5假型载体 |
| WO2015085238A1 (en) | 2013-12-05 | 2015-06-11 | The Regents Of The University Of California, A California Corporation | Inhibitors of lpxc |
| GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
| US20170051267A1 (en) * | 2015-08-20 | 2017-02-23 | Research Foundation Of The City University Of New York | Novel alpha-galactosidase a derivatives |
| BR112020021962A2 (pt) | 2018-04-30 | 2021-01-26 | Amicus Therapeutics, Inc. | construtos para terapia gênica e métodos de uso |
| CN113631182B (zh) | 2018-10-10 | 2025-03-21 | 阿米库斯治疗学公司 | 二硫键稳定的多肽组合物和使用方法 |
-
2019
- 2019-10-10 CN CN201980078576.0A patent/CN113631182B/zh active Active
- 2019-10-10 WO PCT/US2019/055679 patent/WO2020077114A2/en not_active Ceased
- 2019-10-10 CA CA3115944A patent/CA3115944A1/en active Pending
- 2019-10-10 EP EP19797444.7A patent/EP3863663A2/en active Pending
- 2019-10-10 BR BR112021006829-5A patent/BR112021006829A2/pt not_active IP Right Cessation
- 2019-10-10 KR KR1020217013640A patent/KR102743734B1/ko active Active
- 2019-10-10 EA EA202190999A patent/EA202190999A1/ru unknown
- 2019-10-10 AR ARP190102882A patent/AR116624A1/es not_active Application Discontinuation
- 2019-10-10 AU AU2019359385A patent/AU2019359385B2/en active Active
- 2019-10-10 MX MX2021004188A patent/MX2021004188A/es unknown
- 2019-10-10 SG SG11202103640VA patent/SG11202103640VA/en unknown
- 2019-10-10 JP JP2021520223A patent/JP7577650B2/ja active Active
- 2019-10-10 US US16/598,960 patent/US11097015B2/en active Active
- 2019-10-14 TW TW108136956A patent/TW202027781A/zh unknown
-
2021
- 2021-04-09 CL CL2021000883A patent/CL2021000883A1/es unknown
- 2021-04-09 IL IL282205A patent/IL282205A/en unknown
- 2021-04-09 PH PH12021550789A patent/PH12021550789A1/en unknown
- 2021-06-30 US US17/363,333 patent/US12064485B2/en active Active
-
2024
- 2024-08-19 US US18/808,596 patent/US20250242057A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512689A5 (https=) | ||
| ES2371913T3 (es) | Constructos mejorados para expresar polipéptidos lisosomales. | |
| TWI808169B (zh) | 基因治療構築體及使用方法 | |
| JP2021521851A5 (https=) | ||
| CN113631182B (zh) | 二硫键稳定的多肽组合物和使用方法 | |
| CA3159018A1 (en) | Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders | |
| CA3133453A1 (en) | Recombinant adeno-associated virus vectors | |
| CA3120105A1 (en) | Therapeutic adeno-associated virus for treating pompe disease | |
| JP2022552254A (ja) | バリアントｉｇｆ２構築体 | |
| US20220133906A1 (en) | Vectors comprising a nucleic acid encoding lysosomal enzymes fused to a lysosomal teargeting sequence | |
| CN119876200A (zh) | 密码子优化的补体因子i | |
| JP2024519819A (ja) | 眼疾患および障害を処置するための方法および組成物 | |
| IL298178A (en) | Compositions useful for treatment of pompe disease | |
| US20240318157A1 (en) | Neurotensin Variants And Tagged Proteins Comprising Neurotensin Or Sortilin Propeptide | |
| JP2025515030A5 (https=) | ||
| EP4516913A1 (en) | Aav vector optimized for intrathecal administration into which hepatocyte growth factor gene is introduced | |
| US20240271115A1 (en) | Methods and compositions for depleting antibodies | |
| KR102814185B1 (ko) | 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물 | |
| JP2024546578A5 (https=) | ||
| HK40053744A (zh) | 二硫键稳定的多肽组合物和使用方法 | |
| KR20250110842A (ko) | 대사질환을 위한 유전자 요법 구성체 | |
| HK40039189A (en) | Gene therapy constructs and methods of use | |
| KR20250080845A (ko) | 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물 | |
| RU2021101685A (ru) | Оптимизированные гены cln5 и кассеты для их экспрессии, и их применение | |
| HK40053744B (zh) | 二硫键稳定的多肽组合物和使用方法 |